MAID chemotherapy regimen as a treatment strategy for metastatic malignant ameloblastoma: A case report
Li, Xu, Sun, Qiao, Wang, Liu (2019) MAID chemotherapy regimen as a treatment strategy for metastatic malignant ameloblastoma: A case report Medicine (Baltimore) (IF: 1.6) 98(25) e15873
Full text
Click the PDF icon to view the full text of the paper
Abstract
Ameloblastoma is generally characterized as a benign tumor originating in odontogenic epithelium. However, few cases of metastatic malignant ameloblastoma have also been reported. Due to the low incidence of malignant ameloblastoma, there is no established treatment regimen. To explore effective treatment for malignant ameloblastoma, we reported this case study.This report described a case of a 28-year-old malignant ameloblastoma female patient with multiple metastasis (brain and lung).The patient presented ameloblastoma of the left mandible in 2012. Three years later, local recurrence and brain metastasis was observed during a follow-up examination. Five years later, malignant ameloblastoma was detected by imaging and immunohistochemistry in the bilateral multiple pulmonary nodules and mediastinal lymph nodes.The patient was initially treated with tumor resection. Three years later after local recurrence and brain metastasis, she was accepted the extensive mandibulectomy supplemented with brain stereotactic body radiotherapy (SBRT). When diagnosed with pulmonary metastasis, the patient received combined chemotherapy regimen of MAID (mesna, adriamycin, ifosfamide and dacarbazine) for 6 cycles.The efficacy evaluation was partial remission (PR) after the 6 cycles of MAID. The last patient follow-up was July 24th 2018, and no evidence of progression was observed. The progression-free survival (PFS) of the patient was more than 9 months.Surgical resection is the optimal treatment for locally recurrent ameloblastoma. SBRT may be an effective treatment for unresectable oligometastasis of malignant ameloblastoma. Finally, combined chemotherapy of MAID showed encouraging effects in the management of metastatic malignant ameloblastoma.
Links
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6636961http://www.ncbi.nlm.nih.gov/pubmed/31232921
http://dx.doi.org/10.1097/MD.0000000000015873
